Algernon Pharmaceuticals Inc (AGNPF)

[medchem]

I am not commenting on more patients being added to the trial. I am only commenting on them conducting a preliminary analysis with MORE patients included in the analysis. This DOES increase statistical power. And we don't need to make assumptions here, there are two key facts. It's an OPEN trial, so they could tell whether patients are getting better or not, and then decide to analyze an increased fraction of the patients to improve the chance of finding signal AND also they went against their word, they broke the golden rule of clinical trials. If you say you're going to analyze data on 75, then give the result for 125 (for example), that's unethical, there's a conflict of interest, it's clear that's to try and improve signal when you suspect it's poor. And im not assuming they looked at the data. I know it's an open trial so they could see the lack of result before their very eyes...

there's no accountability here, the general public aren't scientists, so they are unlikely to say something when the company which has nobody to hold it accountable decides to change the number in the analysis to improve signal.. people need to open their eyes. this is manipulation... it's unethical...